The stock has a 36-month beta value of -0.38. Opinions on the stock are mixed, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for SAVA is 39.16M, and at present, short sellers hold a 30.54% of that float. On April 05, 2024, the average trading volume of SAVA was 668.02K shares.
SAVA) stock’s latest price update
Cassava Sciences Inc (NASDAQ: SAVA)’s stock price has plunge by -0.49relation to previous closing price of 20.58. Nevertheless, the company has seen a 0.29% surge in its stock price over the last five trading sessions. GlobeNewsWire reported 2024-03-04 that AUSTIN, Texas, March 04, 2024 (GLOBE NEWSWIRE) — Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced plans to present a virtual oral presentation at the International Conference on Alzheimer’s and Parkison’s Disease (AD/PD 2024) taking place in Lisbon, Portugal from March 5-9, 2024.
SAVA’s Market Performance
Cassava Sciences Inc (SAVA) has experienced a 0.29% rise in stock performance for the past week, with a -4.34% drop in the past month, and a -13.66% drop in the past quarter. The volatility ratio for the week is 4.10%, and the volatility levels for the past 30 days are at 5.61% for SAVA. The simple moving average for the past 20 days is 0.72% for SAVA’s stock, with a -4.52% simple moving average for the past 200 days.
Analysts’ Opinion of SAVA
Many brokerage firms have already submitted their reports for SAVA stocks, with B. Riley Securities repeating the rating for SAVA by listing it as a “Neutral.” The predicted price for SAVA in the upcoming period, according to B. Riley Securities is $44 based on the research report published on November 16, 2022 of the previous year 2022.
Cantor Fitzgerald, on the other hand, stated in their research note that they expect to see SAVA reach a price target of $100. The rating they have provided for SAVA stocks is “Neutral” according to the report published on July 15th, 2021.
Maxim Group gave a rating of “Buy” to SAVA, setting the target price at $190 in the report published on July 07th of the previous year.
SAVA Trading at -8.39% from the 50-Day Moving Average
After a stumble in the market that brought SAVA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -36.20% of loss for the given period.
Volatility was left at 5.61%, however, over the last 30 days, the volatility rate increased by 4.10%, as shares surge +3.23% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -21.29% lower at present.
During the last 5 trading sessions, SAVA rose by +0.29%, which changed the moving average for the period of 200-days by -16.75% in comparison to the 20-day moving average, which settled at $20.37. In addition, Cassava Sciences Inc saw -9.02% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at SAVA starting from ROBERTSON SANFORD, who purchase 30,000 shares at the price of $17.45 back on Aug 23 ’23. After this action, ROBERTSON SANFORD now owns 886,851 shares of Cassava Sciences Inc, valued at $523,500 using the latest closing price.
Barry Richard, the Director of Cassava Sciences Inc, purchase 16,571 shares at $16.65 during a trade that took place back on Aug 22 ’23, which means that Barry Richard is holding 293,477 shares at $275,907 based on the most recent closing price.
Stock Fundamentals for SAVA
Current profitability levels for the company are sitting at:
- -45.29 for the present operating margin
- 0.35 for the gross margin
The net margin for Cassava Sciences Inc stands at -40.28. The total capital return value is set at -0.77. Equity return is now at value -53.27, with -50.31 for asset returns.
Currently, EBITDA for the company is -104.43 million with net debt to EBITDA at 1.15. When we switch over and look at the enterprise to sales, we see a ratio of 325.43. The receivables turnover for the company is 2.44for trailing twelve months and the total asset turnover is 0.02. The liquidity ratio also appears to be rather interesting for investors as it stands at 9.13.
Conclusion
To sum up, Cassava Sciences Inc (SAVA) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
